After emerging victorious in a protracted trade secrets dispute last year, Medytox has received billions of dollars in license fees and royalty fees and bought a stake in the U.S. botulinum toxin maker Evolus, becoming its second largest stakeholder.
Daewoong Pharmaceutical’s Foister tablets received a nod from the government for Phase 3 clinical trials as a preventive drug, the company said Monday.
Daewoong Pharmaceutical will receive government funding to establish production facilities for its Covid-19 treatment candidate. The company will receive a maximum 19 trillion won ($17.2 billion) from the Ministry of Health and Welfare by until 2021.
After a two-year investigation, the U.S. International Trade Commission has made a final determination in favor of Medytox in its high-profile “Botox brawl” with Daewoong Pharmaceutical.
Daewoong Pharmaceutical’s Covid-19 drug candidate has won approval to undergo Phase 1 clinical trials in Korea, the company said Monday.
The Botox war between Medytox and Daewoong Pharmaceutical has taken an unexpected turn as the U.S. International Trade Commission (ITC) decided to partially review its initial determination in favor of Medytox.
The U.S. International Trade Commission (ITC) made an initial determination Monday. It concluded that Daewoong’s botulinum toxin product, Nabota, was made with bacteria and intellectual property stolen from Medytox.